Publications by authors named "Paul Cockrum"

Claim this Profile
C
Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma.
Syvart Dennen, Marty Masek, Paul Cockrum, Elizabeth Nagelhout, Ravi Paluri

J Health Econ Outcomes Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world clinical outcomes and economic burden of metastatic pancreatic ductal adenocarcinoma: a systematic review.
Paul Cockrum, Syvart Dennen, Audrey Brown, Jonathon Briggs, Ravi Paluri

Future Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal Adenocarcinoma.
Prachi Bhatt, Jared Hirsch, Paul Cockrum, George Kim, Gabriela Dieguez

J Health Econ Outcomes Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preferences of patients and physicians in the United States for relapsed/refractory follicular lymphoma treatments.
Caitlin Thomas, Kevin Marsh, Myrto Trapali, Nicolas Krucien, Gavin Worth, Paul Cockrum

Cancer Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors.
Callisia N Clarke, Paul Cockrum, Thomas J R Beveridge, Michelle Jerry, Donna McMorrow

J Health Econ Outcomes Res· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma.
Kenneth H Yu, Paul Cockrum, Andy Surinach, Neil Lamarre, Shu Wang

Cancer Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Costs by Site of Service for Commercially-Insured Patients with Metastatic Pancreatic Cancer Receiving Guideline-Recommended Chemotherapy: Comparing Community Oncology and Hospital Outpatient Settings.
Samantha Tomicki, Gabriela Dieguez, David DeStephano, Melody Chang, Paul Cockrum

Clinicoecon Outcomes Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
George Kim, Paul Cockrum, Andy Surinach, Shu Wang, Zev Wainberg

Curr Med Res Opin· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Rawad Elias, Paul Cockrum, Andy Surinach, Shu Wang, Bong Chul Chu

Oncologist· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States.
Ravi Paluri, Ashley Laursen, Joseph Gaeta, Shu Wang, Andy Surinach, Paul Cockrum

Oncologist· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma.
Kenneth H Yu, Muhammet Ozer, Paul Cockrum, Andy Surinach, Shu Wang

Cancer Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
Ben George, Matthew Kent, Andy Surinach, Neil Lamarre, Paul Cockrum

Front Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan.
Kenneth H Yu, Andrew E Hendifar, Olatunji B Alese, Amber Draper, Maen Abdelrahim, Paul Cockrum

Front Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Cost of Care for Commercially Insured versus Medicare Patients with Metastatic Pancreatic Cancer Who Received Guideline-Recommended Therapies.
Samantha Tomicki, Gabriela Dieguez, Helen Latimer, Paul Cockrum, George Kim

Am Health Drug Benefits· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma.
George P Kim, Andy Surinach, Frank A Corvino, Paul Cockrum, Bruce Belanger

Future Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes.
Eileen M O'Reilly, Paul Cockrum, Andy Surinach, Zheng Wu, Allison Dillon

Cancer Med· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan.
Jim Koeller, Andy Surinach, Steven R Arikian, Marko Zivkovic, Patrick Janeczko, Paul Cockrum

Ther Adv Med Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits.
John D Sheppard, Paul C Cockrum, Angela Justice, Mark C Jasek

Ophthalmol Ther· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits.
John D Sheppard, Paul C Cockrum, Angela Justice, Mark C Jasek

Ophthalmol Ther· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An ex vivo human aqueous humor-concentration comparison of two commercial bromfenac formulations.
Thomas R Walters, Robert J Smyth-Medina, Paul C Cockrum

Clin Ophthalmol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.
Gail L Torkildsen, Paul Cockrum, Edward Meier, William M Hammonds, Bruce Silverstein

Curr Med Res Opin· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients.
Richard Lindstrom, Stephen Lane, Andrew Cottingham, Stephen Smith, Kenneth Sall, Paul Cockrum

J Ocul Pharmacol Ther· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin.
Rudolph S Wagner, David B Granet, Steven J Lichtenstein, Tiffany Jamison, Joseph J Dajcs, Paul Cockrum

Clin Ophthalmol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: Association between moxifloxacin ophthalmic solution and fungal infection in patients with corneal ulcers and microbial keratitis.
Stephen S Lane, David W Stroman, Paul Cockrum

J Ocul Pharmacol Ther· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis.
David B Granet, Mark Dorfman, David Stroman, Paul Cockrum

J Pediatr Ophthalmol Strabismus· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis